Ladenburg Thalmann Financial Services’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Buy	+13	New	+$754	﹤0.01%	5167

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BCLI Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2019: 13 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #5167 among its holdings.

43 funds tracked by Wall St. Rank hold BCLI as of Q4 2019.

Ladenburg Thalmann Financial Services held 13 shares of BRAINSTORM CELL THERAPUTC worth $1K as of Q4 2019.
BRAINSTORM CELL THERAPUTC was a new Ladenburg Thalmann Financial Services position in Q4 2019.
BRAINSTORM CELL THERAPUTC made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5167 holding.
43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.